. "klinisch onderzoek"@nl . . . . . "ensayu cl\u00EDnicu"@ast . . . . "252"^^ . . . . . . . "2019-04-30T00:00:00Z"^^ . . . . . . . . . "Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid\u00AE) Alone and in Combination With Epoetin Alfa (Procrit\u00AE) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . . . . . "18"^^ . . . . "Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia"@en . . . . . . . . . "Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia"@en . "NCT00843882" . . . "2009-01-29T00:00:00Z"^^ . . . "Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "clinical trial"@en . . .